To ensure a successful drug launch, biotech companies must start their commercialization planning at least 18 months in advance. This lead time is essential for deeply understanding the patient journey, identifying treatment barriers, and aligning clinical trials with outcomes that truly matter to patients and payers.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

CEO Michael Metzger views the high-risk, capital-intensive clinical development phase as a "project" focused on investment and milestones. The organization only transitions into a "business" at the key turning point of drug approval and commercial launch. This mental model helps manage resources and expectations through the long, uncertain pre-commercial journey.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Instead of viewing regulatory affairs as a final compliance hurdle, involve them at the earliest stages. Their input on market needs and application can strategically shape the drug's design and development process, distinguishing a mere "drug" from a viable "product."

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.